Accessibility Menu
 
Arrow-Thin-Down
S&P 500
6,816.89
-0.1%
-7.77
Arrow-Thin-Down
DJI
47,916.57
-0.6%
-269.23
Arrow-Thin-Down
NASDAQ
22,902.89
+0.4%
+80.48
Arrow-Thin-Down
Bitcoin
$70,949.00
-0.7%
-$533.14
Arrow-Thin-Down
AMZN
$238.43
+2.0%
+$4.78
Arrow-Thin-Down
GOOG
$315.70
-0.2%
-$0.67
Arrow-Thin-Down
META
$629.75
+0.2%
+$1.36
Arrow-Thin-Down
MSFT
$370.82
-0.6%
-$2.25
Arrow-Thin-Down
NVDA
$188.67
+2.6%
+$4.76
Arrow-Thin-Down
TSLA
$348.76
+0.9%
+$3.14
Most Active StocksDaily Stock GainersDaily Stock Losers

An FDA Advisory Committee Kill Shot

Shares plunge 50% as Aveo Pharmaceutical's kidney cancer drug gets a 13-1 "no" vote.

By Dave Williamson – May 2, 2013 at 7:12PM EST

In this video, health-care analyst David Williamson walks investors through today's Aveo Pharmaceuticals (AVEO +0.00%) bloodbath. Shares are down 50% as an FDA advisory committee voted overwhelmingly against its drug candidate tivozanib. Find out why the decision shook out like it did, and if Aveo is a bad news buy after today's extreme plunge.

Read Next

About the Author

Dave Williamson
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
XMFGreenwave4
X@motleydavid

Stocks Mentioned

Pfizer Stock Quote
Pfizer
NYSE: PFE
$26.91
(-1.16%)-$0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services